Protagonist Therapeutics (PTGX) Operating Income (2017 - 2025)
Historic Operating Income for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$46.4 million.
- Protagonist Therapeutics' Operating Income fell 1198.47% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 8725.25%. This contributed to the annual value of $252.8 million for FY2024, which is 36998.14% up from last year.
- Latest data reveals that Protagonist Therapeutics reported Operating Income of -$46.4 million as of Q3 2025, which was down 1198.47% from -$42.0 million recorded in Q2 2025.
- In the past 5 years, Protagonist Therapeutics' Operating Income ranged from a high of $206.3 million in Q1 2024 and a low of -$46.4 million during Q3 2025
- Over the past 5 years, Protagonist Therapeutics' median Operating Income value was -$36.0 million (recorded in 2023), while the average stood at -$10.8 million.
- In the last 5 years, Protagonist Therapeutics' Operating Income tumbled by 33651.57% in 2021 and then surged by 67274.65% in 2024.
- Over the past 5 years, Protagonist Therapeutics' Operating Income (Quarter) stood at -$37.0 million in 2021, then rose by 1.35% to -$36.5 million in 2022, then surged by 163.12% to $23.0 million in 2023, then surged by 450.05% to $126.8 million in 2024, then plummeted by 136.62% to -$46.4 million in 2025.
- Its last three reported values are -$46.4 million in Q3 2025, -$42.0 million for Q2 2025, and -$19.3 million during Q1 2025.